Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06116682 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 248 → 271 locations Eligibility criteria expanded, about 45 words · Secondary endpoints: details revised at 4 of 4 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 45 words
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Study sites: 213 to 248v10
  3. Study sites: 99 to 213v9
  4. Study sites: 83 to 99v8
  5. Primary endpoint revised Study sites: 35 to 83 · Completion date: May 2029 to May 31, 2028 · Eligibility criteria shortened, about 25 words · 1 morev7 Show 4 more changesShow less
    • Study sites: 35 to 83
    • Completion date: May 2029 to May 31, 2028
    • Eligibility criteria shortened, about 25 words
    • Study description shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

Show 5 earlier versionsHide 5 earlier versions
  1. Start date changed from estimate of Dec 16, 2024 to Nov 19, 2024v6
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 16, 2024 to Dec 16, 2024 · Study sites: 0 to 35v5 Show 2 more changesShow less
    • Start date: Sep 16, 2024 to Dec 16, 2024
    • Study sites: 0 to 35
  3. Start date: Jul 16, 2024 to Sep 16, 2024v4
  4. Start date: May 16, 2024 to Jul 16, 2024v3
  5. Start date: Feb 16, 2024 to May 16, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Trial Details
NCT Number NCT06116682
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Lung Non-Small Cell Carcinoma
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov